Multiple myeloma is a complex form of plasma cell cancer that is currently untreatable. There are approximately 200,000 new diagnoses each year globally, with a 100% relapse rate and 54% five-year overall survival rate. In spite of significant advancements in treating blood-related cancers, these diseases continue to be a substantial cause of illness and death worldwide.
In this presentation, Dr. Todd Druley, MD, Ph.D., Chief Medical Officer of Mission Bio, and Co-Founder and Chief Technology Officer Dr. Adam Sciambi, Ph.D:
• Discuss the clinical impact and horizon of multiple myeloma therapies
• Present a novel approach to multiple myeloma therapeutic development by correlating SNVs, CNVs, and surface epitopes for clonal profiling
• Share clinical data generated by researchers from The Cancer Research Center of Toulouse IUCT-Oncopole and Genentech
